Coya Therapeutics

14 articles about Coya Therapeutics

• Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023

  3/31/2023

  Coya Therapeutics, Inc., a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, announced the presentation of results from an academic clinical study in patients with Alzheimer’s Disease with Coya’s COYA 301, its proprietary investigational proprietary biologic.

• Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results

  3/29/2023

  Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells (Tregs) function, today announced its financial results for fiscal year ended December 31, 2022, and provided a clinical and business update.

• Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer

  3/27/2023

  Coya Therapeutics, Inc. today announced the appointment of Arun Swaminathan, Ph.D. to the role of Chief Business Officer.

• Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET

  3/23/2023

  Coya Therapeutics, Inc. today announced management will present at the Virtual Investor Summit on Wednesday, March 29, 2023 at 11:00am ET.

• Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET

  3/21/2023

  Coya Therapeutics, Inc. today announced it will host a conference call to present positive clinical data announced earlier today, of Coya’s proprietary investigational biologic combination, COYA 302, in patients with Amyotrophic Lateral Sclerosis (ALS), today at 8:00am ET.

• Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

  3/21/2023

  Coya Therapeutics, Inc. today reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to ameliorate disease progression.

• Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

  3/20/2023

  Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced a worldwide agreement with Dr. Reddy’s Laboratories Limited.

• Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET

  3/9/2023

  Coya Therapeutics, Inc. today announced it will host a conference call to present clinical data of Coya’s proprietary investigational biologic combination, COYA 302, in patients with Amyotrophic Lateral Sclerosis (ALS), on Tuesday, March 21, 2023 at 8:00am ET.

• Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

  2/27/2023

  Coya Therapeutics, Inc. today announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary investigational biologic combination at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, to be held in-person and virtually from March 19 to March 22, 2023.

• Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate

  2/15/2023

  Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”) today announced expansion of its exclusive worldwide rights for the development and commercialization of COYA 301, the Company’s low-dose IL-2 subcutaneous administration product candidate.

• Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023

  2/2/2023

  Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”) today announced plans for presenting proof-of-concept clinical data from two open-label academic studies conducted at Houston Methodist Hospital, under the leadership of Professor Stanley Appel, MD, the Chair of Coya’s Scientific Advisory Board.

• Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

  1/26/2023

  Coya Therapeutics, Inc. announced the recent publication of an article entitled “Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s Disease” in the peer reviewed journal Acta Neuropathologica Communications.

• Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering

  1/3/2023

  Coya Therapeutics, Inc. (“Coya” or the “Company”) (Nasdaq: COYA) today announced the closing of its initial public offering of 3,050,000 shares of its com mon stock and accompanying warrants to purchase up to 1,525,000 shares of common stock.

• Coya Therapeutics, Inc. Announces Pricing of $15.25 Million Initial Public Offering

  12/29/2022

  Coya Therapeutics, Inc. announced the pricing of its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock.